## 5 Conclusions  
More than half of patients (57.1%; 95%CI = 27-87%) with peri-implantitis who undergo surgical reconstructive therapy may present wound dehiscences. This complication is associated with mandibular location, poor interproximal hygiene, and membrane exposure. The findings of this study should be interpreted with caution due to its retrospective design, the lack of a control group, and the small sample size. Future large-sample randomized clinical trials with a control group and a longer follow-up are required to confirm the reported findings. A.A.: study concept/design, data collection and curation, and drafting of the manuscript. X.C.-B. : study concept/design and data collection. R.F. : study concept/design, data interpretation, funding acquisition, critical review, and approval of the manuscript. E.V.-C.: study concept/design, data interpretation, supervision, critical review, and approval of the manuscript. A.S.-T.: study concept/design and data analysis and interpretation, statistics, critical review, and approval of the manuscript. M.G.-G.: study concept/design, data analysis/interpretation, supervision, and drafting and approval of the manuscript. All authors have read and agreed to the published version of the manuscript. This research received no external funding. The study protocol was approved by the Ethics Committee (CEIm) of the University of Barcelona Dental Hospital (Ref. : 41/2024; Approval date: 13 February 12025), and the study was conducted in accordance with the Declaration of Helsinki [70] on human studies. The patients were given full information about the surgical procedures and signed a written informed consent. Patient consent was waived because we only reviewed the medical files, photographs, and radiographic images of the patients anonymously, and there was no intervention or investigation of humans directly. The original contributions presented in this study are included in the article. Further inquiries can be directed to the corresponding author. **Acknowledgments:** This work was partially funded through a research agreement between the University of Barcelona and Dentaid SL (Catedra UB-DENTAID). **Conflicts of Interest:** The authors have no financial or other interests directly related to the products or information mentioned in this paper. Dr. [PERSON] and Dr. [PERSON] report no conflicts of interest. Dr. [PERSON] reports grants, personal fees, and non-financial support from MozoGrau (Valladolid, Spain), Avinent (Santpedor, Spain), Inibas Dental (Llica de Vall, Spain), and Dentaid SL (Cerdanyola del Valles, Spain), non-financial support from Nobel Biocare (Zurich, Switzerland), and personal fees from Geistlich Pharma AG (Wolhusen, Switzerland), BioHorizons Iberica (Madrid, Spain), Araguaney Dental (Barcelona, Spain), Septodont (Saint-Maur-des-fosses, France), Dentaid SL (Cerdanyola del Valles, Spain), and Laboratorios Silanes (Mexico City, Mexico) outside of the submitted work. Dr. [PERSON] has also participated as a principal investigator in a randomized clinical trial sponsored by Mundipharma (Cambridge, UK), and in another clinical trial as a co-investigator for Menarini Richerche (Florence, Italy). Dr. [PERSON] reports grants, personal fees, and non-financial support from MozoGrau (Valladolid, Spain), Avinent (Santpedor, Spain), Inibas Dental (Llica de Vall, Spain), and Dentaid SL (Cerdanyola del Valles, Spain), non-financial support from Nobel Biocare (Zurich, Switzerland), and personal fees from Laboratorios Silanes (Mexico City, Mexico) outside of the submitted work. Dr. [PERSON] has also participated as an investigator in randomized clinical trials sponsored by Geistlich Pharma AG (Wolhusen, Switzerland), Mundipharma (Cambridge, UK), and Menarini Richerche (Florence, Italy). Dra. [PERSON] reports grants, personal fees, and nonfinancial support from MozoGrau (Valladolid, Spain), Mundipharma (Cambridge, UK), and Unither Pharmaceuticals (Paris, France) outside of the submitted work. Dra.